Levin Resigns Unexpectedly, Street Grills Teva’s Chairman On Viability Of Corporate Governance
This article was originally published in The Pink Sheet Daily
Chairman Philip Frost cited “slight differences” with Teva’s board as the reason that Jeremy Levin resigned. Analysts on a same day call grilled the chairman on Teva’s practice to deny corporate executives a seat on its board, and on the resulting misalignment of board and management objectives.
You may also be interested in...
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.